This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2004-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2004-2010
Title: Michael R Robinson: Innovator in Ocular Therapeutics
Introduction
Michael R Robinson is a prominent inventor based in Kensington, MD (US). He has made significant contributions to the field of ocular therapeutics, particularly in the development of innovative drug delivery devices. With a total of 2 patents, Robinson's work focuses on enhancing the delivery of therapeutic agents to the eye.
Latest Patents
Robinson's latest patents include groundbreaking ocular implant devices designed for the controlled and sustained delivery of therapeutic agents to the eye. These devices encompass both dual mode and single mode drug delivery systems. The patents detail implants suitable for subconjunctival and intravitreal placements, along with fabrication and implementation techniques associated with these unique ocular implant devices.
Career Highlights
Michael R Robinson is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to focus on advancing ocular therapeutic technologies that can significantly improve patient outcomes.
Collaborations
Robinson has collaborated with notable colleagues in his field, including Karl G Csaky and Peng Yuan. These partnerships have contributed to the development and refinement of his innovative ocular delivery systems.
Conclusion
Michael R Robinson's contributions to ocular therapeutics through his patents and work at the National Institutes of Health highlight his commitment to improving healthcare solutions. His innovative approaches in drug delivery systems are paving the way for advancements in the treatment of eye conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile